



RECEIVED

9200

DAC

FEB 25 2005

TECH CENTER 1600/2900

PATENT

Docket No.: 1662/49502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : SINGER ET AL.
SERIAL NO. : 09/552,485
FILING DATE : April 18, 2000
FOR : NOVEL SYNTHESIS AND CRYSTALLIZATION OF
PIPERAZINE RING-CONTAINING COMPOUNDS
GROUP ART UNIT : 1624
EXAMINER : K. Habte
CUSTOMER NO.: 23838

PETITION UNDER 37 CFR § 1.181

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants hereby petition the Office to correct the official record in PAIR and to send us an official communication granting the benefit of Provisional Application No. 60/182,745 in the above identified application, 09/552,485. Attached are copies of a Request for Continued Examination and an Amendment accompanying the RCE filed on August 13, 2002 in 09/552,485 (also attached is a copy of a postcard receipt proving that the Office did receive the RCE and Amendment on August 13, 2002). The Office Action mailed August 26, 2002 also acknowledged having received the documents applicants filed on August 13, 2002. In the Amendment of August 13, 2002, applicants amended the first sentence of the specification to read "This application claims the benefit of U.S. Provisional Application Serial No. 60/130,047,

filed April 19, 1999 and U.S. Provisional Application Serial No. 60/182,745 filed February 16, 2000.”


Since 09/552,485 was filed within 12 months of the filing of 60/182,745, the requirements of 35 U.S.C. 119(e) were met concerning the claiming of the benefit of 60/182,745. In addition, the requirements of 37 CFR 1.78(a)(4), in effect when 09/552,485 was filed on April 18, 2000, were also met by the Amendment filed on August 13, 2002 concerning amending the specification to claim the benefit of 60/182,745. Thus, the benefit of 60/182,745 should be accorded to 09/552,485.

Also attached is a copy of a Corrected Filing Receipt in a CIP application, 10/206,344, of 09/552,485 showing that 09/552,485 claims the benefit of 60/130,047 and 60/182,745.

Since the instant Petition is necessitated by an error on the part of the Office, no fees are believed due. However, the Commissioner is authorized to charge any fees that may be required in relation to this Petition to Deposit Account 11-0600, referencing Attorney Docket No. 01662/49502.

Respectfully submitted,


Date: February 18, 2005



King L. Wong
Registration No. 37,500

Attachments

KENYON & KENYON
1500 K Street, N.W., Suite 700
Washington, D.C. 20005-1257
Tel.: (202) 220-4200

**RECEIVED**

FEB 25 2005

TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/206,344	07/29/2002	1624	740	1662/49504	0	13	2

CONFIRMATION NO. 1562

23838
KENYON & KENYON
1500 K STREET, N.W., SUITE 700
WASHINGTON, DC 20005

CORRECTED FILING RECEIPT



OC000000008903211

Date Mailed: 10/03/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Claude Singer, Kfar Saba, ISRAEL;
Anita Liberman, Tel Aviv, ISRAEL;
Nina Finkelstein, Herzliya, ISRAEL;

Domestic Priority data as claimed by applicant

This application is a CIP of 09/552,485 04/18/2000
which claims benefit of 60/130,047 04/19/1999
and claims benefit of 60/182,745 02/16/2000

Foreign Applications**If Required, Foreign Filing License Granted 08/30/2002****Projected Publication Date: 12/12/2002****Non-Publication Request: No****Early Publication Request: No****Title**


Novel synthesis and crystallization of piperazine ring-containing compounds

10/2/02

RECEIVED
FEB 25 2005
TECH CENTER 1600/2900

The stamp of the Patent Office hereon may be taken as acknowledging the receipt, on the date stamped, of

INVENTOR(S): SINGER ET AL.
SERIAL NO.: 09/552,485
FILED: April 18, 2000
TITLE: NOVEL SYNTHESIS AND CRYSTALLIZATION OF
PIPERAZINE RING-CONTAINING COMPOUNDS



GROUP ART UNIT: 1624

The PTO is authorized to charge any fees associated with this filing to
Deposit Account No. 11-0600

PAPERS FILED:

**Fee Transmittal, Request for Continued Examination
(RCE) and Amendment.**

WDW:bcl

August 13, 2002

1662/49502

DC01 399312 v 1

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.
See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/552,485
Filing Date	April 18, 2000
Examiner Name	K. HABTE
First Named Inventor	SINGER ET AL.
Group Art Unit	1624
Attorney Docket Number	1662/49502

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.
NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

a. ☒ Previously submitted

- Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on July 11, 2002.
(Any unentered amendment(s) referred to above will be entered).
- ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on
- ☐ Other

b. Enclosed

- ☒ Amendment/Reply
- ☐ Affidavit(s)/Declaration(s)
- ☐ Information Disclosure Statement (IDS)
- ☐ Other

This application claims the benefit of U.S. Provisional Application Serial No. 60/130,047, filed April 19, 1999, and U.S. provisional Application Serial No. 60/182,745, filed February 16, 2000.

2. Miscellaneous

- ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
- ☐ Other

3. Fees

The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 11-0600
 - ☒ RCE fee required under 37 C.F.R. § 1.17(e)
 - ☒ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
 - ☐ Other
 - ☒ Charge any additional fees under 37 C.F.R. § 1.16 and 1.17
- ☐ Check in the amount of \$ _____ enclosed
- ☐ Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print /Type)	W. David Wallace	Registration No. (Attorney/Agent)	42,210
Signature	<i>W. David Wallace</i>	Date	August 13, 2002

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:

Name (Print /Type)	
Signature	Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patents, Box RCE, Washington, DC 20231.

RECEIVED
FEB 25 2005

TECH CENTER 1600/2900



**FEE TRANSMITTAL
for FY 2002**

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$) 1,140.00**Complete If Known**

Application Number	09/552,485
Filing Date	April 18, 2000
First Named Inventor	Singer et al.
Examiner Name	K. Habte
Group / Art Unit	1624
Attorney Docket No.	1662/4950

METHOD OF PAYMENT (check one)

- 1.
- ☒
- The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit
Account
Number

11-0600

Deposit
Account
Name

KENYON & KENYON

- ☒
- Charge Any Additional Fee Required
-
- Under 37 CFR 1.16 and 1.17
-
- ☐
- Applicant claims small entity status.
-
- See 37 CFR 1.27

- 2.
- ☐
- Payment Enclosed:

☐ Check ☐ Credit card ☐ Money
Order ☐ Other**FEE CALCULATION****1. BASIC FILING FEE**

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1)

(\$)

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
-20 **	X		
-3 **	X		
	X		

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$)

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet.	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	400.00
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17 (q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	740.00
169	900	169	900	Request for expedited examination of a design application	


Other fee (specify)

*Reduced by Basic Filing Fee Paid


SUBTOTAL (3)

(\$)1,140.00

SUBMITTED BY**Complete (if applicable)**

Name (Print/Type)	W. David Wallace	Registration No. Attorney/Agent)	42,210	Telephone	202.220.4200
Signature				Date	August 13, 2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**Burden Hour Statement:** This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PATENT
Docket No.: 1662/49502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : SINGER ET AL.
SERIAL NO. : 09/552,485
FILING DATE : April 18, 2000
FOR : NOVEL SYNTHESIS AND CRYSTALLIZATION OF
PIPERAZINE RING-CONTAINING COMPOUNDS
GROUP ART UNIT : 1624
EXAMINER : K. Habte

RECEIVED
FEB 25 2005
TECH CENTER 1600/2900

Amendment

ASSISTANT COMMISSIONER FOR
PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

A Request for Continued Examination has been filed concurrently herewith. Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks. Applicants enclose the fee for a two-month extension of time; however, the Commissioner is authorized to charge or debit any underpayment or overpayment to Deposit Account 11-0600.

IN THE SPECIFICATION:

On page 1, please substitute the following paragraph for paragraph 1:

-- This application claims the benefit of U.S. provisional Application Serial No. 60/130,047, filed April 19, 1999, and U.S. provisional Application Serial No. 60/182,745, filed February 16, 2000.--

IN THE CLAIMS:

Please cancel claims 29, 36, and 42-45 without prejudice or disclaimer.

Please amend claims 30, 31, 37, 38 and 41 as follows:

30. (Amended) A crystalline adduct of mirtazapine and water containing up to about three weight percent water.
31. (Amended) The adduct of mirtazapine and water of claim 30 prepared by precipitation from a solvent comprising water and either an alcohol or acetone.
37. (Amended) A crystallized adduct of mirtazapine and water prepared by:
 - i) crystallizing mirtazapine from a solution comprising water;
 - ii) recovering crystallized mirtazapine; and
 - iii) drying the crystallized mirtazapine until the crystallized mirtazapine contains up to about 3 percent water.
38. (Amended) The adduct of mirtazapine and water of claim 37 wherein the solution also comprises an alcohol.
41. (Amended) The adduct of mirtazapine and water of claim 40 wherein the solution comprises a ratio of ethanol:water ranging from about 1:1 to about 1:4.

Please add new claims 46-53 as follows:

46. (New) A process for preparing crystallized mirtazapine comprising the steps of:
 - i) dissolving mirtazapine in an organic solvent, thereby forming a solution;
 - ii) adding water to the solution;
 - iii) precipitating mirtazapine; and
 - iv) drying the precipitated mirtazapine under conditions sufficient to produce crystallized mirtazapine having up to about 3% by weight water.
47. (New) The process of claim 46, wherein the organic solvent is selected from the group consisting of methanol, ethanol, and isopropyl alcohol.
48. (New) The process of claim 46, wherein the drying conditions comprise elevated temperature and reduced pressure.

49. (New) The process of claim 48, wherein the elevated temperature is about the reflux temperature of the organic solvent.
50. (New) The process of claim 46, wherein the dissolving step comprises refluxing the organic solvent.
51. (New) The process of claim 46, wherein the adding step comprises adding water dropwise to the solution.
52. (New) The process of claim 46, wherein the precipitating step comprises cooling the solution to about 10 °C.
53. (New) The process of claim 47,
wherein the dissolving step comprises refluxing the organic solvent;
wherein the adding step comprises adding water dropwise to the solution;
wherein the precipitating step comprises cooling the solution to about 10 °C; and
wherein the drying conditions comprise heating the precipitated mirtazapine to the reflux temperature of the organic solvent under reduced pressure.

REMARKS

The foregoing claim amendments were not entered when submitted on July 11, 2002, under 37 CFR § 1.116. Therefore, claims 29-45 are currently pending in the application. Entry of the foregoing amendments is respectfully requested. Upon entry of the amendments, claims 30-35, 37-41, and 46-53 will be pending.

Applicants have also amended the specification to add a claim of priority to a second provisional application.

Applicants' undersigned attorney will contact the Examiner shortly to request and arrange an interview.

In view of the foregoing amendments and the remarks of record, Applicants respectfully request allowance of the pending claims. The Examiner is invited to contact the undersigned attorney regarding any matter concerning the pending application.

Date: 8/13/02

Respectfully submitted,



W. David Wallace
Registration No. 42,210

KENYON & KENYON
1500 K Street, N.W., Suite 700
Washington, D.C. 20005-1257
Tel.: (202) 220-4200
Fax.: (202) 220-4201

MARKED-UP VERSION OF AMENDMENTS

IN THE SPECIFICATION:

This application claims the benefit of U.S. provisional Application Serial No. 60/130,047, filed April 19, 1999, and U.S. provisional Application Serial No. 60/182,745, filed February 16, 2000.

IN THE CLAIMS:

30. [The] A crystalline adduct of mirtazapine and water [of claim 29] containing up to about three weight percent water.
31. [An] The adduct of mirtazapine and water of claim 30 prepared by precipitation from a solvent comprising water and either an alcohol or acetone.
37. A[n] crystallized adduct of mirtazapine and water prepared by:
1. slow addition of water at elevated temperature to a mixture of mirtazapine and an organic solvent selected from the group consisting of alcohols and acetone,
 2. precipitating the adduct by cooling, and
 3. separating the adduct from the water and organic solvent.]
- i) crystallizing mirtazapine from a solution comprising water;
- ii) recovering crystallized mirtazapine; and
- iii) drying the crystallized mirtazapine until the crystallized mirtazapine contains up to about 3 percent water.
38. The adduct of mirtazapine and water of claim 37 wherein the [organic solvent is] solution also comprises an alcohol.
41. The adduct of mirtazapine and water of claim 40 wherein [from about one to about four volumes of water are added relative to the amount of ethanol] the solution comprises a ratio of ethanol:water ranging from about 1:1 to about 1:4.